Clinical Trial

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Study acronym: MC2TCR
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2023 (before its estimated December 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-25; most recent amendment 2023-12-01.
Trial Details
NCT Number NCT04729543
Lead Sponsor Erasmus Medical Center
Collaborators: Ludwig Institute for Cancer Research, Dutch Cancer Society, Stichting Coolsingel Rotterdam grant, Jan Ivo Stichting grant
Conditions Melanoma, Melanoma, Uveal, Head and Neck Cancer
Enrollment 20 participants
Start Date 2020-10-20
Primary Completion 2024-12-20 (estimated)
Study Completion 2027-10-20 (estimated)
Updated on ClinicalTrials.gov 2023-12-04